The European Commission has granted marketing authorization to Samsung Bioepis' biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, is the first hematology biosimilar from Samsung Bioepis to be approved in the European Union.
Samsung Bioepis’ Epysqli, an eculizumab biosimilar, was approved in Europe after the European Commission (EC) granted the product marketing authorization. The biosimilar the first approval for a hematology biosimilar developed by the company in the European Union.
Epysqli references Soliris (reference eculizumab) and will be used to treat adult and pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that happens when part of the immune system attacks and damages red blood cells and platelets. It is the second eculizumab biosimilar approved in the European Union, following the approval of Amgen's Bekemv (ABP 959).
“The approval of Epysqli, Samsung Bioepis’ first hematology biosimilar, reflects our ongoing endeavors to introduce more treatment options for PNH patients in Europe…. The approval marks another step towards enhancing the lives of patients, including those with rare diseases, through our pioneering and innovative use of science and technology,” said Byoungin Jung, vice president and regulatory affairs team leader at Samsung Bioepis, in a company statement.
The EC approval was based on evidence from analytical, in vitro, nonclinical, and clinical studies. Data from a randomized, double-blind, multicenter, cross-over phase 3 study comparing the effects of Epysqli with the reference product found that the 2 drugs had similar safety, efficacy, pharmacokinetic, pharmacodynamic, and immunogenicity profiles. The results of the analysis were shared at the 2022 European Hematology Association Congress.
The study evaluated the change in lactate dehydrogenase (LDH) levels from baseline in patients with PNH, who were randomized to receive either the biosimilar or reference product (n = 25 patients in each group). Overall, 50 patients with PNH were enrolled in the analysis.
Patients received a 600-mg intravenous dose weekly of the first drug in the treatment group for 4 weeks and 900 mg for the fifth week, followed by 900-mg doses administered every 2 weeks until week 26, when patients were switched to receive the second drug. The patients remained on the second drug until week 50.
In total, 49 patients received treatment with a study drug and 46 completed the full 50 weeks. The mean difference in LDH level measured at week 26 between the biosimilar and the reference product was 34.48 (95% CI, –47.66 to 116.62).
Epysqli is the seventh biosimilar developed by Samsung Bioepis to receive approval for use in Europe following Benepali (etanercept biosimilar; January 2016), Flixabi (infliximab biosimilar; May 2016), Imraldi (adalimumab biosimilar; August 2017), Ontruzant (trastuzumab biosimilar; November 2017), Aybintio (bevacizumab biosimilar; August 2020), and Byooviz (ranibizumab biosimilar; August 2021).
The news comes after the European Medicines Agency’s Committee for Medicinal Products for Human Use gave a positive opinion for Bekemv, another eculizumab biosimilar that was developed by Alexion Pharmaceuticals, in February 2023.
Additionally, Amgen announced in August 2022 that it completed a phase 3 trial for its eculizumab biosimilar candidate, saying that the study met primary end points and confirmed the biosimilarity between the biosimilar and Soliris in patients with PNH.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.